The upgrade is based on Moody's expectation of robust earnings growth for Eli Lilly in the coming years. This growth is ...
Eli Lilly’s profit doubled in the fourth quarter ... jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 billion. Both figures ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback